Curatis Shows Significant Revenue Growth and Progress in Development Pipeline

On September 16, 2024, Curatis Holding AG (SIX:CURN) reported revenue of CHF 2.0 million for H1 2024, solely accounting for Curatis AG's two months of inclusion. The distribution business saw a revenue increase of 31% to CHF 4.3 million compared to the first half of 2023.

The company recorded a loss of CHF 3.8 million, influenced by non-cash effects, such as personnel costs related to the re-evaluation of the stock option plan, and amortization of intangible assets. Transaction costs for the acquisition of Curatis AG amounted to over CHF 1 million.

Curatis submitted the Orphan-Drug Designation application for its lead product candidate, C-PBTE-01, to the FDA and expects a response in Q4 2024. The cash position stands strong at CHF 3.5 million, supporting ongoing operations for the foreseeable future without accounting for potential partner revenue in 2025.